Status:
COMPLETED
Clinical Relevance of Typing HLA-DR7-DQ2
Lead Sponsor:
Corporacion Parc Tauli
Conditions:
Celiac Disease Patients Following Recommendations of ESPGHAN
HLA-DQ2 Typing Include HLA-DR7-DQ2 Haplotypes
Eligibility:
All Genders
Up to 18 years
Brief Summary
Celiac disease patients with HLA-DR7-DQ2 haplotype have the same histological, analytical and clinical behaviour as patients with HLA-DR3-DQ2 haplotype.
Eligibility Criteria
Inclusion
- Diagnosis of celiac disease following ESPGHAN recommendations
- HLA-DQ2 typing including HLA-DR3-DQ2 and HLA-DR7-DQ2 haplotypes
Exclusion
- Patients who have not been diagnosed for celiac disease
- HLA-DQ2 typing that not include HLA-DR7-DQ2 haplotype
Key Trial Info
Start Date :
January 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT01813383
Start Date
January 1 2010
End Date
March 1 2013
Last Update
March 19 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Corporació Sanitària i Universitària Parc Taulí
Sabadell, Barcelona, Spain, 08208